Kingsway Announces Availability of Annual Letter to Shareholders

PR Newswire

ITASCA, Ill., March 29, 2021 /PRNewswire/ – (NYSE: KFS) Kingsway Financial Services Inc. (“Kingsway” or the “Company”) announced today that a letter to its shareholders from John T. Fitzgerald, the Company’s President and CEO, has been made available (the “Letter”). The Letter can be found on the Company’s website at http://bit.ly/kfs2020.

About the Company

Kingsway is a holding company that owns or controls subsidiaries primarily in the extended warranty, asset management and real estate industries. The common shares of Kingsway are listed on the New York Stock Exchange under the trading symbol “KFS.”

Forward-Looking Statements

This press release and/or the Letter may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks” and variations and similar words and expressions are intended to identify such forward-looking statements; however, the absence of any such words does not mean that a statement is a not a forward-looking statement. Such forward-looking statements relate to future events or future performance but reflect Kingsway management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Additional Information

Additional information about Kingsway, including a copy of its 2020 Annual Report and filings on Forms 10-Q and 8-K, can be accessed on the Canadian Securities Administrators’ website at www.sedar.com, on the EDGAR section of the U.S. Securities and Exchange Commission’s website at www.sec.gov or through the Company’s website at www.kingsway-financial.com.

Cision View original content:http://www.prnewswire.com/news-releases/kingsway-announces-availability-of-annual-letter-to-shareholders-301257473.html

SOURCE Kingsway Financial Services Inc.

Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

The company’s findings will be showcased to over 400 clinicians, respiratory health and critical care professionals, aerosol scientists, engineers, product development and regulatory experts

PR Newswire

ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, “Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program,” at the upcoming 23rd International Congress of the International Society for Aerosols in Medicine (ISAM).

The ISAM Congress, which aspires to bring together over 400 attendees at one of the world’s largest pulmonary drug delivery and respiratory health conferences, will be held in Boise, Idaho, May 22 to 26, 2021 with an agenda focused on: Medical Aerosols in the Age of COVID and other pandemics, acute and critical care, the developing world, pulmonary disease, inhaled viruses and viral transmission, health risks from environmental aerosols and emerging aerosol technologies.

In addition to its poster presentation, number 070, the company has been invited to present at the Regulatory/Standardization issues networking group, which recently published an appeal on the urgent need to accelerate the development of inhaled therapies for COVID-19. Presentation date and time has not yet been determined.

In addition, Ampio recently completed enrollment in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19. Prior to launching the trial, Ampio undertook pre-clinical research to establish the safety of its Ampion anti-inflammatory therapy in an inhaled format. Ampion, a novel biologic drug containing a blood-derived cyclized peptide and other small molecules, with the potential for treating a variety of serious and often life-threatening inflammatory conditions, had previously demonstrated its safety utilizing injection and intravenous (IV) delivery formats in other trials.

The FDA identified a need to assess the no-observed adverse effect level (NOAEL) in animals with Ampion via inhalation as the intended route of administration. Ampio designed a study with FDA feedback to assess the potential local toxicity to the lung and other respiratory tissues at a range of inhalation doses. The company’s presentation will highlight the program as an example of efficient development that is responsive to both the COVID-19 pandemic and FDA requirements.

The 23rd ISAM Congress is being held as a hybrid event. All posters will be posted both on the website – along with a short 2-to-5-minute oral presentation – and printed for display at the Boise Conference Center. For more details on the ISAM Congress and the timing of Ampio’s presentation, visit: www.isam.org

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily focused on the development of Ampion, our product candidate, to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (“BPCIA”).

Forward Looking Statements

Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (“BLA”), the ability of Ampio to enter  into partnering arrangements,  clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts

Investor Relations

Joe Hassett

[email protected]

484-686-6600

Media Contact

Katie Kennedy

[email protected]

610-731-1045

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-present-at-the-international-society-for-aerosols-in-medicine-isam-23rd-international-congress-301257174.html

SOURCE Ampio Pharmaceuticals, Inc.

Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory

PR Newswire

DENVER, March 29, 2021 /PRNewswire/ — Theralink Technologies, Inc. (OTC: OBMP), a precision medicine and molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical and Public Health License from the State of California for its Golden, Colorado laboratory, effective March 11th, 2021.

The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the California CLIA License allow Theralink to accept and perform testing on human specimens from California. The California Clinical and Public Health License survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.

“We are thrilled to receive the California Clinical and Public Health License for our Golden, CO laboratory as this was truly a team effort. Receiving the California licensure is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights that may improve cancer treatment for breast cancer patients,” said Mick Ruxin, M.D., President & CEO of Theralink Technologies, Inc. “With the Clinical and Public Health License from the State of California, we expect to begin receiving, testing and billing for patient’s breast cancer tumor specimens in California in Q2 2021.”


About Theralink Technologies, Inc.

Theralink Technologies is a proteomics-based, molecular profiling and precision medicine company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.


Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.

 

Cision View original content:http://www.prnewswire.com/news-releases/theralink-technologies-achieves-major-milestone-california-clinical-and-public-health-license-for-its-golden-co-laboratory-301256563.html

SOURCE Theralink Technologies

Entravision Launches Fuego Radio Format in the Las Vegas and Palm Springs Markets

Entravision Launches Fuego Radio Format in the Las Vegas and Palm Springs Markets

SANTA MONICA, Calif.–(BUSINESS WIRE)–
Entravision Communications Corporation:

WHAT:

Entravision Communications Corporation (NYSE: EVC), a leading global media and marketing technology company, today announced its Fuego Radio format is expanding into two new owned and operated stations in the Las Vegas (92.7 FM) and Palm Springs (103.5 FM) markets beginning on March 29, 2021. This follows Fuego Radio’s expansion into the Santa Barbara-Santa Maria affiliate (97.1 FM) market on January 6, 2021.

 

 

 

Fuego Radio presents a music mix ignited by today’s top trending global Latin Urban music movement mixed with Contemporary Hits, including recent chart topping artists such as Ariana Grande, Dua Lupa, Cardi B, Olivia Rodrigo, Drake, The Weeknd and Bruno Mars. In addition to hit music offerings, each morning Fuego Radio listeners can enjoy the antics of Edgar “Shoboy” Sotelo, on the popular Shoboy Show. This feel-good entertainment experience is real, relatable and fun and targets young adults that prefer entertainment in English with a Latin vibe. The Shoboy Show is also featured on Fuego Stations in Sacramento, Stockton and Modesto, California, Albuquerque, New Mexico, Salt Lake City, Utah and Harlingen, Brownsville and McAllen, Texas.

 

 

WHERE:

KRTO-FM, Santa Barbara-Santa Maria — as of January 6, 2021

 

KRRN-FM, Las Vegas and KPST-FM, Palm Springs — as of March 29, 2021

 

 

QUOTE:

“Following the expansion of our popular Fuego Radio format into the Santa Barbara-Santa Maria market in January, we are thrilled to also introduce this format into the Las Vegas and Palm Springs markets,” said Entravision’s Nestor Rocha, Vice President of Audio. “The Shoboy Show has been a great success in all of our markets, and we anticipate this momentum to continue in Las Vegas and Palm Springs as well.”

 

Contact for Affiliation:

Marisol Rodriguez
[email protected]

323-900-6310

Contact for Ad Sales:

Las Vegas:

Chris Jordan, SVP

[email protected]

702-507-1047

Palm Springs:

Bob McCauley, SVP

[email protected]

760-797-8401

Contact for Entravision:

Kimberly Esterkin

ADDO Investor Relations

[email protected]

310-829-5400

KEYWORDS: United States North America California Nevada

INDUSTRY KEYWORDS: Blogging Other Communications Consumer Electronics Technology Public Relations/Investor Relations Audio/Video Marketing Advertising Communications Celebrity TV and Radio Music Entertainment Internet Mobile/Wireless

MEDIA:

Logo
Logo

Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease

Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease

— Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia –

— GOCOVRI is the first and only therapy for the treatment of OFF and/or dyskinesia for patients with Parkinson’s disease on levodopa-based therapy –

EMERYVILLE, Calif.–(BUSINESS WIRE)–
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson’s disease”in the peer-reviewed journal Frontiers in Neurology. GOCOVRI® (amantadine) extended release capsules is the first and only medicine approved as a treatment both for dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing OFF episodes.

The publication examined data from two pivotal, placebo-controlled Phase 3 clinical studies evaluating a total of 196 patients. The results demonstrated that treatment with GOCOVRI more than doubled the daily time patients spent ON without any dyskinesia (whether troublesome or non-troublesome), from 3.9 hours a day at baseline to 8.4 hours at Week 12. Compared to placebo, those treated with GOCOVRI experienced an additional 2.9 hours ON time without dyskinesia, an increase driven by a reduction in both OFF time and dyskinesia. Typically, PD clinical trials for the treatment of motor complications differentiate dyskinesia into ‘troublesome’ and ‘non- troublesome’ categories. This analysis is unique in evaluating treatment impact by measuring the increase in ON time without any dyskinesia. GOCOVRI-related adverse events were consistent with the known safety profile of amantadine.

“Patients prefer to experience ON time without any dyskinesia, so balancing the need for levodopa-based treatment to reduce OFF time that comes with a risk of increased dyskinesia is a challenge for patient care in Parkinson’s disease,” said Robert A. Hauser, M.D., MBA, Professor of Neurology and Director of the Parkinson’s Disease and Movement Disorders Center at the University of South Florida. “These results expand the knowledge of GOCOVRI’s efficacy as an adjunctive treatment to levodopa to address both motor complications.”

“This publication highlights GOCOVRI’s ability to improve ON time with no dyskinesia – which can make a significant impact on better movement control for someone living with PD motor complications,” said Adrian Quartel, M.D., Chief Medical Officer, Adamas. “As the only treatment that addresses both ends of the spectrum in PD motor complications, we are proud to publish data that continue to support GOCOVRI as a treatment option that may help people with Parkinson’s increase good movement throughout the day.”

This publication analyzed self-reported diary data from pivotal trials, where participants recorded their predominant motor state every 30 minutes for two days prior to each clinic visit. These diary recordings may not be reflective of their typical daily or weekly experience.

About Parkinson’s disease, OFF, and dyskinesia

Parkinson’s disease (PD) is a progressive, neurodegenerative disorder caused by the gradual loss of brain cells that produce the neurotransmitter dopamine and affects approximately one million people in the United States. Dopamine decline in the brain results in a wide range of motor (movement-related) and non-motor symptoms. As the disease progresses, people taking levodopa-based therapy are likely to experience reemergence or sudden return of stiffness, rigidity, and tremors between medication doses referred to as OFF episodes, which may be unpredictable. The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia. The abrupt and unpredictable transitions between episodes of dyskinesia, normal movement, and OFF lead to a considerable impact on patients’ lives.

About GOCOVRI

GOCOVRI® (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes.

Taken once daily at bedtime, GOCOVRI provides an initial lag (delayed release) and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day (extended release). Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension.

For more information about GOCOVRI, please visit www.GOCOVRI.com.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GOCOVRI® is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2

WARNINGS AND PRECAUTIONS

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

ADVERSE REACTIONS

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and, orthostatic hypotension.

Please see full Prescribing Information for additional important safety information at https://www.gocovri.com/assets/pdfs/Gocovri_Prescribing_Information.pdf.

About Adamas

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and, society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Source: Adamas Pharmaceuticals, Inc.

Media:

Sarah Mathieson

Vice President of Corporate Communications

510-450-3528

[email protected]

Investors:

Peter Vozzo

Managing Director, Westwicke

443-213-0505

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology FDA Mental Health Health Pharmaceutical

MEDIA:

Logo
Logo

Anna Marie Smith Appointed Executive Vice President & Chief Human Resources Officer

ASHEVILLE, N.C., March 29, 2021 (GLOBE NEWSWIRE) — The board of directors of HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank” or “HTB”), today announced that Anna Marie Smith assumed the position of Chief Human Resources Officer (CHRO) of both the Company and the Bank effective March 29, 2021. Ms. Smith will lead the HTB team responsible for diversity and inclusion initiatives, employee engagement, and the traditional human resource areas of: employee relations, benefits and compensation, talent management, recruiting and training. She will serve as a member of the Strategic Operating Committee (SOC) and report directly to Dana Stonestreet, Chairman & President of the Company and Chief Executive Officer of HTB.

Smith brings more than 25 years of experience leading diverse and high-performing teams while successfully driving large-scale initiatives. During her tenure at Wells Fargo (formerly Wachovia Bank), she led the team responsible for learning & development for over 10,000 employees nationally, oversaw mentorship programs, diversity & inclusion programs, and was the leader responsible for HR services to executive and mid-level managers. More recently at Forsyth Tech Community College, Smith served as the strategic leader for human resources, facilities, construction, and campus police across eight campus locations. She is a sought-after speaker in both business and academic settings.

“Anna Marie’s deep experience leading and inspiring teams to greater heights makes her the ideal executive to strategically reposition HTB’s Human Resources function to meet the demands of the changing landscape,” says Dana Stonestreet, Chairman & Chief Executive Officer. “I look forward to working with Anna Marie to further expand professional opportunities for our staff and to continue offering a highly coveted workplace in all of the markets HomeTrust serves. I am confident Anna Marie’s demonstrated success serving employees across all levels of an organization will strengthen our culture of employee engagement that leads to high levels of customer satisfaction.”

Smith is a graduate of the Indiana University of Pennsylvania in Indiana, PA with a Bachelor of Science in Hotel, Restaurant & Institutional Management. She earned a Master of Business Administration from the University of North Carolina at Greensboro. Prior to joining HTB, she served as Vice President of HR & Administrative Services at Forsyth Tech Community College in Winston-Salem NC, and as SVP, Learning & Development Senior Manager of Wells Fargo. Smith has served various volunteer board positions including with Family Services, Inc., Victory Junction, and the Children’s Home Society of North Carolina.

About HomeTrust Bancshares, Inc.

HomeTrust Bancshares, Inc. is the holding company for HomeTrust Bank. As of December 31, 2020, the Company had assets of $3.7 billion. The Bank, founded in 1926, is a North Carolina state chartered, community-focused financial institution committed to providing value added relationship banking through over 40 locations as well as online/mobile channels. Locations include: North Carolina (including the Asheville metropolitan area, the “Piedmont” region, Charlotte, and Raleigh/Cary), Upstate South Carolina (Greenville), East Tennessee (including Kingsport/Johnson City/Bristol, Knoxville, and Morristown) and Southwest Virginia (including the Roanoke Valley). The Bank is the second largest community bank headquartered in North Carolina.

www.htb.com

www.hometrustbancshares.com

Contact: Dana L. Stonestreet
  Chairman and Chief Executive Officer
  828.259.3939

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c0454ba-65a1-40f8-845d-f74d3898ef4e



BioSig Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021

Westport, CT, March 29, 2021 (GLOBE NEWSWIRE) —

  • Company expands clinical footprint, installations and commercial sales with leading hospitals
  • Neurostimulation division to develop a novel sensing and stimulation technology to optimize neurostimulation therapies and develop novel solutions to diagnose and treat neurological disorders; the Company licensed a first utility patent from the Mayo Foundation for Medical Education and Research
  • Launched artificial intelligence effort with leading partners
  • Balance sheet remains robust with $28.3 million in cash, cash equivalent, and short-term investments, well-positioned for 2021, based on current expectations

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued a Letter to Shareholders providing highlights on the Company’s recent developments and updates.

Recent Company highlights include:

  • Updates on the commercial adoption of the PURE EP™ System, including the first commercial sale of three units to St. David’s HealthCare in Austin, TX, an HCA Healthcare-owned hospital.
  • More than 643 patient cases have been conducted with the PURE EP™ System by 40 physicians across eight clinical sites to date.
  • At least three more clinical sites are scheduled to commence the evaluation in the coming months, including the New York-Presbyterian/Weill Cornell Medical Center and the Michigan Medicine–University Hospital that maintain two of the most extensive electrophysiology programs in the country.
  • The PURE EP™ System received favorable reviews during leading industry conferences, including EPLive 2020 and the 26th Annual International AF Symposium 2021. Complete recordings of the presentations and articles authored by the physician users and independent reviewers of the technology are available on the Company’s website.
  • The Company launched an initiative to develop and commercialize novel AI- and machine learning-powered software solutions. The program will be conducted under the leadership of Mayo Clinic and Dr. Alexander Wissner-Gross, a leading AI scientist at M.I.T.
  • The Company deployed innovative Vuzix M400 Smart Glasses for remote servicing and training, allowing its customers uninterrupted access to its technical team.
  • The NeuroClear™ division is developing a novel nerve sensing and stimulation technology to improve current treatments for resistant hypertension and other nerve-related therapeutic targets.
  • The Company reports $28.3 million in cash as of December 31, 2020, positioning the Company well for commercial and operational growth, based on the Company’s current expectations and projections.

“We made some significant strides in 2020, which have laid the foundation for a strong 2021,” stated Kenneth L. Londoner, Founder, Chairman, and CEO of BioSig Technologies, Inc. “Commercial adoption of the PURE EP™ System is gaining momentum, and we continue to add new healthcare facilities and complete more patient cases. Commercialization, innovation, and growth remain at the forefront of our strategic priorities as we expand our clinic footprint and strengthen our product positions and service offerings. We have a strong balance sheet, we are progressing well with our neurostimulation division, and are looking to the future of next-generation AI- and machine learning-powered software for our PURE EP™ System with a new strategic initiative that we are launching with the Mayo Foundation for Medical Education and Research. BioSig is well-positioned to have an excellent 2021, and we look forward to executing on many opportunities that we believe will drive shareholder value.”

To view the Company’s Shareholder Letter in its entirety, please visit https://ir.biosig.com.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.



Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
[email protected]
203-409-5444, x133

Immersive Tech, a Victory Square Technologies Portfolio Company, Announces C$1.5 Million Non-Brokered Private Placement

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that its portfolio company Fantasy 360 Technologies Inc. d/b/a Immersive Tech (“Immersive”) has launched a non-brokered private placement of up to 4,285,714 subscription receipts of Immersive (“Subscription Receipts”) at a price of CAD$0.35 per Subscription Receipt for aggregate gross proceeds of up to CAD$1,500,000 (the “SR Offering”). The Subscription Receipts will be issued pursuant to and governed by a subscription receipt agreement to be entered between Immersive and an escrow agent to be appointed by Immersive on or prior to the closing date of the SR Offering (the “SR Agreement”). The proceeds of the SR Offering, minus 10% which will be immediately released to Immersive on closing of the SR Offering for the purposes of satisfying the Escrow Release Conditions (as defined below) and for working capital and general corporate purposes, will be deposited in escrow pursuant to the SR Agreement.

In accordance with the SR Agreement, each Subscription Receipt shall be automatically converted without any further action on the part of the holder thereof into one unit of Immersive (each, a “SR Unit”) upon the satisfaction of certain escrow release conditions (the “Escrow Release Conditions”) including the receipt of conditional approval by Immersive with respect to the listing of the common shares of Immersive (“Immersive Shares”) on the Canadian Securities Exchange (the “CSE”) and the receipt of a final prospectus of Immersive in the Province of British Columbia. If the Escrow Release Conditions are not satisfied by August 31, 2021, the proceeds of the SR Offering will be returned to the subscribers.

Each SR Unit will consist of one Immersive Share and one-half of one Immersive Share purchase warrant (each whole warrant, an “SR Warrant”). Each SR Warrant will entitle the holder thereof to purchase one additional Immersive Share at a price of CAD$0.52 for a period of 24 months following the completion of a going-public transaction by Immersive. Immersive may accelerate the expiry date of the SR Warrants to 30 days following Immersive issuing a news release accelerating the expiry date of the SR Warrants in the event the closing price of the Immersive Shares on the CSE or any equivalent exchange upon which the Immersive Shares trade is equal to or greater than $0.78 per Immersive Share for a period of ten (10) consecutive trading days.

Immersive intends to use the net proceeds from the SR Offering to finance acquisitions, organic growth investments and for general working capital purposes. Finder’s fees may be paid to eligible finders in accordance with the policies of the CSE consisting of a cash commission of up to 6% of the gross proceeds raised under the SR Offering and finder warrants (“Finder Warrants”) in an amount up to 6% of the number of Subscription Receipts sold pursuant to the SR Offering. Each Finder Warrant will have the same terms as the SR Warrants.

Closing of the SR Offering is subject to customary closing conditions including, but not limited to, receipt of any required regulatory approvals. The securities being offered under the private placement will be issued pursuant to available exemptions from the prospectus requirements under applicable securities laws and will be subject to a hold period that will expire four months and one day from the later of: (i) the date of issue, and (ii) the date on which Immersive becomes a reporting issuer in any jurisdiction in Canada.

For more information please contact Alexandros Tzilios at [email protected].

About Immersive

As an industry leader in blending amusement park engineering and video game development, Immersive has established strong working relationships with top organizations including: Bayer Pharmaceuticals, Intel, Allegiant Airlines, Capital One, Scotia Bank, and the US Food and Drug Administration among others for brand activations at events including X-Games, Boston Hub Week among others. Over the past four years. Immersive has built highly sought after escape room experiences for some of the largest Family Entertainment groups globally including APEX Entertainment, and Kalahari Resorts. Immersive also operates the newly launched company “UNCONTAINED”, the world’s first COVID-safe free-roam AR/VR shipping container Location-Based Entertainment franchise. For more info view the company’s latest highlight reel video or visit www.ImmersiveTech.co

US Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

On behalf of the Board of Directors

“Shafin Diamond Tejani”
Director and Chief Executive Officer
Victory Square Technologies Inc.
www.victorysquare.com

For further information about Victory Square, please contact:

Investor Relations 
Contact – Edge Communications Group
Email: [email protected]
Telephone: 604 283-9166

Media Relations Contact – Howard Blank, Director
Email: [email protected]
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed for fast-track growth. VST’s sweet spot is cutting-edge tech that’s shaping the 4th Industrial Revolution. Our corporate portfolio consists of 20 global companies using AI, VR/AR, and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups

VST isn’t your ordinary investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.

What we do differently for investors

VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF). For investors, we offer early-stage access to the next unicorns before they’re unicorns. Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we’re able to provide strong and stable returns while also tapping into emerging global trends with big upsides.

For more information, please visit www.victorysquare.com

Forward Looking Statement

Certain statements in this news release related to Victory Square and Immersive are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the SR Offering, the listing of the Immersive Shares, the business and prospects of Immersive, the ability of Immersive to complete the SR Offering, the ability of Immersive to arrange for finders and an escrow agent on commercially reasonable terms, the intended use of proceeds of the SR Offering, the filing of the final prospectus of Immersive and the obtaining of receipts for the final prospectus. There are numerous risks and uncertainties that could cause actual results and the Victory Square’s and Immersive’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Immersive’s and Victory Square’s business in general; (iii) that the proceeds of the SR Offering may need to be used for purposes other than as set out in this news release; (iv) that Immersive may not be able to complete the SR Offering as contemplated; (v) that Immersive may not be able to complete its going-public transaction as contemplated; (vi) other risks and uncertainties set forth in Victory Square’s public disclosure documents; (vii) risks and uncertainties common in the industries in which Immersive and Victory Square operate; and (viii) other factors beyond the control of Victory Square and/or Immersive. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Information relating to Immersive expressed herein is derived solely from management of Immersive. Except as required by applicable law, neither Immersive nor Victory Square intends to update these forward-looking statements.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.



Points International Announces Closing of its C$31.6 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Points International Ltd. (TSX: PTS) (Nasdaq: PCOM) (“Points” or the “Company”), the global leader in powering loyalty commerce, is pleased to announce that it has closed its previously announced bought deal public offering, pursuant to which a syndicate of underwriters led by Acumen Capital Finance Partners Limited (the “Lead Underwriter”) and including Cormark Securities Inc., RBC Dominion Securities Inc., and Scotia Capital Inc. (together with the Lead Underwriter, the “Underwriters”) purchased, on a bought deal basis, 1,687,510 common shares of Points (“Common Shares”) at a price of $18.75 per Common Share (the “Offering Price”) for aggregate gross proceeds to the Company of approximately $31.6 million, including full exercise of the Underwriters’ over-allotment option (the “Offering”).

The Common Shares were offered by way of short form prospectus in all of the Provinces of Canada. The Company intends to use the net proceeds of the Offering to fund the advancement of (i) its product road map; (ii) data analytics, marketing automation and machine learning capabilities; and (iii) other future growth opportunities. The net proceeds may also be used to accelerate the Company’s business development pipeline.

About Points

Points, (TSX: PTS) (Nasdaq: PCOM) is a trusted partner to the world’s leading loyalty programs, leveraging its unique Loyalty Commerce Platform to build, power, and grow a network of ways members can get and use their favourite loyalty currency. Our platform combines insights, technology, and resources to make the movement of loyalty currency simpler and more intelligent for nearly 60 reward programs worldwide. Founded in 2000, Points is headquartered in Toronto with teams operating around the globe.

For more information, visit Points.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares in the United States nor shall there be any sale of the Common Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Common Shares offered under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States. Accordingly, the Common Shares offered under the Offering may not be offered or sold in the United States or to U.S. persons unless an exemption from registration is available.

Caution Regarding Forward-looking Statements

This press release contains or incorporates forward-looking statements within the meaning of United States securities legislation, and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”). These forward-looking statements include the intended use of net proceeds of the Offering. These statements are not historical facts but instead represent only Points’ expectations, estimates and projections regarding future events.

Although Points believes the expectations reflected in such forward-looking statements are reasonable, such statements are not guarantees of future performance and are subject to important risks and uncertainties that are difficult to predict. Certain material assumptions or estimates are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Undue reliance should not be placed on such statements. In particular, uncertainty around the duration and scope of the COVID-19 pandemic and the impact of the pandemic and actions taken in response on global and regional economies, economic activity, and all elements of the travel and hospitality industry may have a significant and materially adverse impact on our business. In addition, the risks, uncertainties and other factors that may impact the results expressed or implied in such forward-looking statements include, but are not limited to: (i) airline or travel industry disruptions, such as an airline insolvency and continued airline consolidation; (ii) our dependence on a limited number of large clients for a significant portion of our consolidated revenue; (iii) our reliance on contractual relationships with loyalty program partners that are subject to termination and renegotiation; (iv) our exposure to significant liquidity risk if we fail to meet contractual performance commitments; (v) our ability to convert our pipeline of prospective partners or launch new products with new or existing partners as expected or planned; (vi) our dependence on various third-parties that provide certain solutions in our Platform Partners segment that we market to loyalty program partners; (vii) the fact that our operations are conducted in multiple jurisdictions and in multiple currencies and as such dramatic fluctuations in exchange rates of the foreign currencies can have a dramatic effect on our financial results and (viii) the risk of an event of default under our senior secured credit facility. These and other important risk factors that could cause actual results to differ materially are discussed in Points’ annual information form, Form 40-F, annual and interim management’s discussion and analysis (“MD&A”), and annual and interim financial statements and the notes thereto. These documents are available at www.sedar.com and www.sec.gov.

The forward-looking statements contained in this press release are made as at the date of this release and, accordingly, are subject to change after such date. Except as required by law, Points does not undertake any obligation to update or revise any forward-looking statements made or incorporated in this press release, whether as a result of new information, future events or otherwise.

Investor Relations Contact

Sean Mansouri, CFA or Cody Slach
Gateway Investor Relations
1-949-574-3860
[email protected]



Dada Group’s JDDJ Celebrates Sixth Anniversary with Key Retail and Brand Partners Awards Ceremony Held Online

PR Newswire

SHANGHAI, March 29, 2021 /PRNewswire/ — Dada Group (Nasdaq: DADA) (“Dada”), China’s leading local on-demand delivery and retail platform, today announces that JDDJ (“JD Daojia”), the on-demand retail platform of Dada, holds its second “Retail and Brand Partners Awards Ceremony” online and jointly recommends the “2020 Retail Digitalization Innovation Cases” together with China Chain Store Association (CCFA), to celebrate JDDJ’s 6th anniversary.

JDDJ’s second “Retail and Brand Partners Awards Ceremony” recognized 45 leading retail and brand partners for their tremendous contributions to improve service and win the recognition of customers on the platform. The three major awards include “Best Strategic Partner for Categories of the Year”, “Most Growing Partner of the Year” and “Best Marketing Partner of the Year”.

Among them, JDDJ named Walmart, Yonghui Supermarket, CR Vanguard, Pagoda, Neptune Drugstore and other 11 merchants as “Best Strategic Partner for Categories of the Year”, which recognized for their long-term collaborative partnerships and achievements in omni-channel expansion, technology innovation and brand marketing, jointly promoting the development of digital transformation of the retail industry in China.

Beijing Hualian Supermarket, Zhongbai Supermarket, 30 Fresh, Jianshengyuan Drugstore, Lenovo Laiku, Watson’s and other 12 merchants were awarded “Most Growing Partner of the Year” by JDDJ. The platform partners with retailers in all categories, including supermarkets, pharmaceuticals, beauty and electronics stores.

Meanwhile, JDDJ also recognized Mengniu, Yili, Yihai Kerry, Mars Wrigley, Nestle and other 6 brand owners as “Best Marketing Partner of the Year”. In the past year, JDDJ and these brand partners worked together to create many omni-channel marketing campaigns, bringing consumers closer, digital marketing more accurate and efficient, and jointly building a new ecology of omni-channel marketing on the platform.

“In the era of micro-e commerce, the booming on-demand retail has become the biggest opportunity and digital transformation is the focus of the retail industry in China. In the past year, digitalization, omni-channel and all-category strategies have become the key words, and JDDJ has created many excellent practice cases together with retail partners,” said Philip Kuai, Founder, Chairman & CEO of Dada Group. “We would like to express our most sincere gratitude to all our ‘new friends’ and ‘old partners’. Thank you for your support, help and trust as always. JDDJ will never compete with retailers and brands, but continues to empower them to create a win-win situation together with everyone.”

“Digital transformation has become a major trend in China’s retail industry, during which a number of pioneering retail enterprises and leading digital empowerment platforms like JDDJ spring up,” said Jianzhen Peng, Secretary General of CCFA. “Together with JDDJ, we have systematically recommended the representative, applicable and worthy cases of retail digital transformation on the platform in 2020. We hope these cases can serve as a business development reference for more retail partners.”

This year’s JDDJ 415 Anniversary Shopping Festival will be launched from April 8 to 18. During the period, JDDJ partners with leading supermarket chains in China, including Walmart, Yonghui Supermarket, CR Vanguard, BBG Supermarket, Aeon, Jiajiayue, Lotus and famous brands, such as Yili, Mengniu, P&G, Unilever, Yihai Kerry, Mars Wrigley, PepsiCo, Nestle, as well as over 100,000 merchant stores on the platform to create an “One-hour Shopping Carnival”. This provides consumers in nearly 1,400 counties and cities in China with “one-hour delivery” services for all categories of products, such as supermarket groceries, fresh meat and eggs, daily necessities, mobile phones and electronics, beauty and clothing.

In order to ensure the safe and timely delivery of consumers’ orders during the festival, Dada Now, the local on-demand delivery platform of Dada Group, has played a key role as the intra-city logistics infrastructure. Before the promotional season, Dada Now has analyzed and anticipated the delivery demand in advance, optimized the efficiency of delivery capacity and improved the stability of its smart logistics system.

About Dada Group

Dada Group is a leading platform of local on-demand retail and delivery in China. It operates JDDJ, one of China’s largest local on-demand retail platforms for retailers and brand owners, and Dada Now, a leading local on-demand delivery platform open to merchants and individual senders across various industries and product categories. The Company’s two platforms are inter-connected and mutually beneficial. The Dada Now platform enables improved delivery experience for participants on the JDDJ platform through its readily accessible fulfillment solutions and strong on-demand delivery infrastructure. Meanwhile, the vast volume of on-demand delivery orders from the JDDJ platform increases order volume and density for the Dada Now platform. In June 2020, Dada Group began trading on the Nasdaq Global Market, under the ticker symbol “DADA.”

Cision View original content:http://www.prnewswire.com/news-releases/dada-groups-jddj-celebrates-sixth-anniversary-with-key-retail-and-brand-partners-awards-ceremony-held-online-301257516.html

SOURCE Dada Group